The predictive and prognostic value of novel biomarkers, including PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), tumor microenvironment (TME), and gut microbiome, is fundamental in the therapeutic approach of utilizing ICI’s (Rosellini et al. 2022). This evidence concerns the gene CD274 and neoplasm.